Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN versus TRELSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN versus TRELSTAR.
SUPPRELIN vs TRELSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH) that acts as a potent inhibitor of gonadotropin secretion. Initially stimulates, then suppresses pituitary gonadotropin release (LH and FSH), leading to decreased testosterone and estrogen production.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced testicular and ovarian steroidogenesis.
50 mcg subcutaneously once daily for the first month, then 25 mcg subcutaneously once daily for maintenance. Alternatively, 7.5 mg intramuscularly once monthly.
3.75 mg intramuscularly once every 4 weeks or 11.25 mg intramuscularly once every 12 weeks or 22.5 mg intramuscularly once every 24 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours following subcutaneous administration; this supports once-daily dosing.
Terminal elimination half-life approximately 3 weeks (21-28 days) after intramuscular injection; sustained release formulation results in prolonged exposure.
Primarily renal, with approximately 70-80% of histrelin excreted unchanged in urine; biliary/fecal excretion accounts for about 20-30%.
Primarily hepatic metabolism; <5% excreted unchanged in urine; fecal elimination of metabolites accounts for approximately 20-30%.
Category C
Category C
GnRH Agonist
GnRH Agonist